Napabucasin: Additional Phase Ib/II data

Data from a cohort of 27 patients with non-small cell lung cancer (NSCLC) in the open-label, North American Phase Ib/II BBI608-201 trial showed that twice-daily oral napabucasin, starting at a dose of

Read the full 326 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE